Ratings Alphamab Oncology

Equities

9966

KYG0330A1013

Market Closed - Hong Kong S.E. Other stock markets 01:38:06 30/04/2024 pm IST			5-day change	1st Jan Change
4.75 ^HKD	+0.21%		+13.91%	-28.46%

10/04	Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting	MT
10/04	Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALPHAMAB ONCOLOGY	-28.46%	584M	-
IQVIA HOLDINGS INC.	+0.17%	42.86B	B
MODERNA, INC.	+10.92%	42.74B	B-
LONZA GROUP AG	+44.30%	41.36B	A
CELLTRION, INC.	-6.20%	27.68B	C
ICON PUBLIC LIMITED COMPANY	+5.23%	25.15B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.63B	B
MEDPACE HOLDINGS, INC.	+26.69%	12.37B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.92B	C+
UNITED THERAPEUTICS CORPORATION	+6.57%	11.21B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes